CA
NZ
UK
AU
IND
US
US stock futures fell Tuesday as rising tensions between the US and Iran revived inflation concerns, with elevated oil prices adding pressure across markets.
TheNasdaqannounced it plans to add an overnight trading session, allowing investors to trade stocks for nearly 23 hours per day.
Home Depot (NYSE: HD) shares are trading higher in premarket action after the company topped Wall Street estimates for fiscal Q2, reporting adjusted EPS of $4.92, versus $4.73 expected, and revenue of $47.86 billion, versus roughly $47.24 billion to $47.27 billion expected.
Solaris Energy Infrastructure (NYSE: SEI) currently trades at $65.50 and has been a strong performer for shareholders, returning 806% since August 2021, well ahead of the S&P 500's 76.8% gain over the same period.
US import prices fell 0.4% in July, marking the steepest monthly drop since May 2025 and coming in well below market expectations for a modest 0.1% increase, according to Bureau of Labor Statistics data. The headline figure was overwhelmingly shaped by energy: fuel import …
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares are up 16% at $24.80 during extended hours ahead of the company's scheduled disclosure of primary data from its Phase 3 LUCIDITY study evaluating avexitide for post-bariatric hypoglycemia on August 18, 2026.
Cue Biopharma, Inc. (NASDAQ: CUE) shares ended the day down 19% at $27.64 after the company disclosed a widened Q2 net loss of $153.1 million, a figure heavily impacted by CUE-221 licensing fees and non-cash acquisition costs.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) shares tumbled 26% to end the day at $0.56 after the company reported third-quarter financial results that missed the mark, posting a GAAP net loss of $0.34 per share, which was $0.09 wider than anticipated.
OmniAb, Inc. (NASDAQ: OABI) shares closed up 13% at $3.82 after the company raised its 2026 year-end cash outlook to $49 million to $53 million, up from $37 million to $41 million, following recent technology licensing and business development activity.
argenx SE (NASDAQ: ARGX) shares rallied 16% to end at $987.84 after the company reported that its Phase 3 ALKIVIA trial of Vyvgart Hytrulo for autoimmune myositis reached its primary endpoint, highlighting a statistically significant 15.4-point TIS improvement in the pooled IMNM/DM group versus …
Please wait processing your request...